Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock

Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock

York, NY - July 28, 2017 - Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or

"the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective

treatment options, announced today the pricing of an underwritten public offering of 21,500,000 shares of its common stock

and warrants to purchase an aggregate of 18,275,000 shares of the Company's common stock at an offering price to the

public of $0.75 per share and related warrant. The warrants have an exercise price of $1.05 per share and have a term of

exercise of five years. The offering is expected to close on or about August 2, 2017, subject to customary closing

& Co. Inc. is acting as sole book-running manager for the offering. Maxim Group LLC and Jones Trading Institutional Services

LLC are acting as co-managers for the offering.

gross proceeds to Actinium from this offering are expected to be approximately $16.125 million, before deducting underwriting discounts

and commissions and other estimated offering expenses payable by Actinium. The Company intends to use the net proceeds from the

offering to fund clinical development of Iomab-B, Actimab-A, Actimab-M, its alpha particle technology platform, and for general

offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective

by the U.S. Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement and accompanying base

prospectus relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will

be filed with the SEC and will be available free of charge on the SEC's website at http://www.sec.gov.

press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein,

nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be

unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Copies of the final prospectus

supplement and accompanying base prospectus relating to the offering may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate

Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8563,

or by e-mail at EquityProspectus@opco.com.

Actinium Pharmaceuticals, Inc.

Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking

effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly

to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed

to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow

transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard

preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium

believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased

transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical

study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product

candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML

age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options

and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle immunotherapy

(APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed

at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more

about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow

@ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.

Statements for Actinium Pharmaceuticals, Inc.

news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995,

including statements regarding the closing of the offering and the anticipated use of proceeds. These statements are based on

management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from

those set forth in the statements. The forward-looking statements may include statements regarding product development, product

potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from

those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as

a result of new information, future events, or otherwise.

Pharmaceuticals, Inc.

Principal Financial Officer